Skip to content

Standardized preparation of platelet rich plasma and its clinical application in the treatment of osteoarthritis

Standardized preparation of platelet rich plasma and its clinical application in the treatment of osteoarthritis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500099913
Enrollment
Unknown
Registered
2025-04-01
Start date
2022-12-27
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis

Interventions

Platelet final concentration group (PLT< 1000×109/L, 1000~1500×109/L, 1500~2000×109/L, 2000~2500×109/L):One hundred and twenty patients with osteoarthritis of the knee were selected and divided into 4
Number of PRP injections (3 groups with less than 2 PRP injections, 3 injections, and 4 or more PRP injections):Ninety patients with osteoarthritis of the knee were selected and divided into three gro
Autoapheresis PRP preservation group (one group is the first use of autoapheresis PRP stored at 22-24 °C, the last two times stored at -80 °C, and the other group is PRP frozen at -80 °C for all three

Sponsors

The 960th Hospital of the PLA Joint Logistics Support Force
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. At least 18 years old, meeting the diagnostic criteria for osteoarthritis of the knee in the Osteoarthritis Diagnostic and Treatment Guidelines (2018 edition). 2. The Kellgren-Lawrecne classification based on X-ray changes is in grade I to III. 3. No anticoagulant drugs such as aspirin and rivaroxaban within 5d. 4. No related therapeutic drugs or treatment measures within 2 weeks. 5. Voluntarily participate in the clinical study and sign the Informed Consent Form.

Exclusion criteria

Exclusion criteria: 1.History of knee trauma and surgery; 2.Combined with rheumatism, rheumatoid arthritis 3.Have congenital deformity of lower limb or abnormal force line;. 4.Combined with haematopoietic system diseases; 5. Other patients who are not suitable for enrollment after evaluation.

Design outcomes

Primary

MeasureTime frame
VAS pain score,;WOMAC score ;Lysholm score;

Countries

China

Contacts

Public ContactHuang Xiangyan

The 960th Hospital of the PLA Joint Logistics Support Force

xiangyan73@aliyun.com+86 159 6970 0616

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026